Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control

Resistance to paclitaxel chemotherapy frequently develops in ovarian cancer. Oncolytic adenoviruses are a novel therapy for human malignancies that are being evaluated in early phase trials. However, there are no reliable predictive biomarkers for oncolytic adenovirus activity in ovarian cancer. We...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Oncol
Main Authors: Ingemarsdotter, Carin K., Tookman, Laura A., Browne, Ashley, Pirlo, Katrina, Cutts, Rosalind, Chelela, Claude, Khurrum, Karisma F., Leung, Elaine Y.L., Dowson, Suzanne, Webber, Lee, Khan, Iftekhar, Ennis, Darren, Syed, Nelofer, Crook, Tim R., Brenton, James D., Lockley, Michelle, McNeish, Iain A.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2014
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528770/
https://ncbi.nlm.nih.gov/pubmed/25560085
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2014.12.007
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados